Li Ding, Xu Jianqiu, Dong Xiaochen, Chen Wenjing, Pan Lingling, Jiang Hao, Pan Jingye, Huang Yueyue
Department of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Key Laboratory of Intelligent Treatment and Life Support for Critical Diseases of Zhejiang Provincial, Wenzhou, China.
J Gastrointest Oncol. 2021 Aug;12(4):1374-1383. doi: 10.21037/jgo-21-267.
Globally, the high morbidity and mortality of gastric carcinoma (GC) have been one of the great challenges facing humanity. However, the early diagnosis of GC is still unknown. Matrilin-3 (MATN3) is a member of the extracellular matrix (ECM) protein family. Previous studies have reported a correlation between the expression of MATN3 and bone disease. However, the role of MATN3 in GC has not been reported in depth, which can have a possible far-reaching implication for GC.
We explored the diagnostic and prognostic value and pathway enrichment of MATN3 expression in GC. Limma package conducted by R was used to analysis the difference expression data of MATN3 from The Cancer Genome Atlas (TCGA). The receiver operating characteristic (ROC) curve analysis was used to estimate the diagnostic value of MATN3 expression. univariate and multivariate analysis were used to assess the prognostic value of MATN3, and gene set enrichment analysis (GSEA) to identify the enriched signaling pathways.
MATN3 was found to be significantly higher in GC tissue samples. GC patients with high MATN3 expression had poor prognosis. Then, GSEA showed that the gene sets were correlated with signaling pathways including ECM receptor interaction, hypertrophic cardiomyopathy (HCM), and glycosaminoglycan biosynthesis chondroitin sulfate, among others.
The study suggests that MATN3 can serve as a potential diagnostic and prognostic biomarker for GC.
在全球范围内，胃癌（GC）的高发病率和高死亡率一直是人类面临的重大挑战之一。然而，GC的早期诊断仍不明确。基质金属蛋白酶3（MATN3）是细胞外基质（ECM）蛋白家族的成员。先前的研究报道了MATN3表达与骨疾病之间的相关性。然而，MATN3在GC中的作用尚未得到深入报道，这可能对GC具有深远的潜在意义。
我们探讨了MATN3在GC中的诊断和预后价值以及通路富集情况。使用R语言的Limma包分析来自癌症基因组图谱（TCGA）的MATN3差异表达数据。采用受试者工作特征（ROC）曲线分析来评估MATN3表达的诊断价值。使用单变量和多变量分析评估MATN3的预后价值，并通过基因集富集分析（GSEA）来识别富集的信号通路。
发现MATN3在GC组织样本中显著升高。MATN3高表达的GC患者预后较差。然后，GSEA显示基因集与包括ECM受体相互作用、肥厚性心肌病（HCM）和硫酸软骨素糖胺聚糖生物合成等信号通路相关。
该研究表明MATN3可作为GC潜在的诊断和预后生物标志物。
